Celltrion Says "Omlyclo Reaches 60% Market Share in Spain in Just Three Months"

Top-ranked supplier in public tenders in Catalunya and the Basque Country
Differentiation from the original with a full lineup of SC formulations

Celltrion's Omlyclo (ingredient name: omalizumab), a treatment for chronic idiopathic urticaria and allergic asthma, has surpassed a 60% market share in Spain just three months after its launch, rapidly accelerating its market expansion.

On the 4th, Celltrion stated, "Since we launched Omlyclo in Spain through direct sales in September last year, we have been expanding public tenders at the state and regional levels and simultaneously increasing supply to individual hospitals, thereby broadening the prescription base." The company added, "Clear demand for Omlyclo from local physicians and patients has been confirmed, and as of the end of last year, we estimate that we have already secured a dominant market share of more than 60% in the local omalizumab market."

Celltrion's Spanish subsidiary is strengthening its marketing activities targeting key stakeholders such as hospitals and healthcare professionals, tendering bodies, and regional governments to promote switching from the original product to Omlyclo. Currently, Omlyclo is being prescribed at more than 260 public and private hospitals across Spain.

At the end of last year, the company achieved its first tender success by being selected as the top-ranked supplier in a public tender in the Catalunya region, one of the country's major areas. It was also chosen as the first-priority supplier in a tender to supply all public healthcare institutions in the Basque Country region, leading to the signing of a supply contract. Recently, Celltrion has continued its push into the Spanish market by participating in omalizumab tenders in the Valencia and Asturias regions as well.

In Spain, Celltrion has launched Omlyclo in an autoinjector (AI) 150 mg formulation, which is not available for the original product, thereby completing a full lineup of subcutaneous (SC) formulations including the existing pre-filled syringe (PFS). The fact that patients can receive reimbursement for the indication of chronic rhinosinusitis with nasal polyps is also cited as a competitive advantage compared to the original.

Based on its performance in Spain, Celltrion plans to swiftly expand Omlyclo prescriptions across Europe. In Norway, where the product was launched first, it recorded a 17% market share in the very first quarter of sales, and in the Netherlands, the company has won tenders from multiple hospital groups, securing supply volumes that cover about 70% of the overall market.

Kang Sukhoon, Head of Celltrion's Spanish subsidiary, said, "Omlyclo is rapidly increasing its influence in the Spanish omalizumab market, leveraging its first-mover status, supply stability, and differentiated competitiveness," adding, "We expect prescription growth to accelerate further once participation in upcoming public tenders and the supply of awarded volumes begin in earnest."

This content was produced with the assistance of AI translation services.